PSA and second-line therapy of hormone refractory prostate carcinoma.
The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was <4 ng/ml. Eight patients (33%) only had a subjective response. However, 75% of the patients with a PSA value <4 ng/ml had a subjective improvement. On the other hand, subjective response was 25% only in patients in whom PSA value decreased to <50% of the initial value but >4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient.
Serretta
V
V
Institute of Urology, University of Palermo, Palermo, Italy. vserrett@mbox.infcom.it
Rizzo
I
I
Contino
G
G
Pavone
C
C
Pomara
G
G
Melloni
D
D
Pavone-Macaluso
M
M
D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*
D017430:Prostate-Specific Antigen